Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$2.20
-2.2%
$1.92
$1.03
$2.64
$440.75M1.471.74 million shs963,664 shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.28
-0.2%
$5.95
$4.35
$12.38
$315.70M0.43209,378 shs1.31 million shs
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.81
-9.0%
$1.94
$1.29
$13.07
$68.00M-0.231.14 million shs4.50 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.41
+1.6%
$6.36
$4.58
$9.78
$371.54M1.85514,411 shs1.89 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.00%-11.29%-3.08%+61.76%+65.41%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
0.00%+3.97%+7.53%+7.17%-16.93%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%0.00%+25.69%-15.02%-59.78%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+16.33%+22.28%+21.88%+7.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
2.9069 of 5 stars
3.73.00.00.02.51.70.6
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
2.6025 of 5 stars
3.61.00.00.03.23.30.0
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
2.6863 of 5 stars
3.61.00.00.03.22.50.6
CryoPort, Inc. stock logo
CYRX
CryoPort
3.4751 of 5 stars
4.42.00.00.01.93.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.33
Buy$8.67293.94% Upside
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.25
Buy$22.00250.32% Upside
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.18
Buy$21.401,082.32% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0048.45% Upside

Current Analyst Ratings Breakdown

Latest BMEA, AURA, ATAI, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/13/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/3/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$7.00
6/2/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/28/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$22.00
5/23/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$5.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/15/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
5/13/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$310K1,421.77N/AN/A$0.69 per share3.19
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$3.04 per shareN/A
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$1.42 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.63N/AN/A$7.44 per share1.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$138.43M-$3.55N/AN/AN/AN/A-197.71%-134.84%7/30/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)

Latest BMEA, AURA, ATAI, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.47-$0.55-$0.08-$0.55N/AN/A
5/14/2025Q1 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
5/5/2025Q1 2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.84-$0.80+$0.04-$0.80N/AN/A
3/31/2025Q4 2024
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$1.00-$0.81+$0.19-$0.81N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
N/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.08
4.07
4.07
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
11.06
11.06
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
2.25
2.25
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24

Institutional Ownership

CompanyInstitutional Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
28.41%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%

Insider Ownership

CompanyInsider Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
26.80%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5.40%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
18.42%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
80200.34 million146.65 millionOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5050.27 million47.55 millionNot Optionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5037.57 million30.65 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.07 millionOptionable

Recent News About These Companies

Cryoport Is Safer Now (Rating Upgrade)
CryoPort Sells CRYOPDP Business to DHL Group

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
atai Life Sciences stock logo

atai Life Sciences NASDAQ:ATAI

$2.20 -0.05 (-2.22%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.20 +0.00 (+0.18%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.28 -0.01 (-0.16%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$7.30 +1.02 (+16.24%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.81 -0.18 (-9.05%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.90 +0.09 (+4.70%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.41 +0.12 (+1.65%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$7.42 +0.01 (+0.13%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.